BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34792199)

  • 21. Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer.
    Kelly JR; Park HS; An Y; Yarbrough WG; Contessa JN; Decker R; Mehra S; Judson BL; Burtness B; Husain Z
    Oral Oncol; 2018 Apr; 79():64-70. PubMed ID: 29598952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
    Mehanna H; Robinson M; Hartley A; Kong A; Foran B; Fulton-Lieuw T; Dalby M; Mistry P; Sen M; O'Toole L; Al Booz H; Dyker K; Moleron R; Whitaker S; Brennan S; Cook A; Griffin M; Aynsley E; Rolles M; De Winton E; Chan A; Srinivasan D; Nixon I; Grumett J; Leemans CR; Buter J; Henderson J; Harrington K; McConkey C; Gray A; Dunn J;
    Lancet; 2019 Jan; 393(10166):51-60. PubMed ID: 30449623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Did the addition of concurrent chemotherapy to conventional radiotherapy improve survival for patients with HPV+ve and HPV-ve Oropharynx cancer? A population-based study.
    Hall SF; Liu FF; O'Sullivan B; Shi W; Rohland S; Griffiths R; Groome P
    Br J Cancer; 2017 Oct; 117(8):1105-1112. PubMed ID: 28829763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triweekly carboplatin as a potential de-intensification agent in concurrent chemoradiation for early-stage HPV-associated oropharyngeal cancer.
    Iganej S; Beard BW; Chen J; Buchschacher GL; Abdalla IA; Thompson LDR; Bhattasali O
    Oral Oncol; 2019 Oct; 97():18-22. PubMed ID: 31421466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
    Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
    Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
    Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
    J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas.
    Huang SH; Xu W; Waldron J; Siu L; Shen X; Tong L; Ringash J; Bayley A; Kim J; Hope A; Cho J; Giuliani M; Hansen A; Irish J; Gilbert R; Gullane P; Perez-Ordonez B; Weinreb I; Liu FF; O'Sullivan B
    J Clin Oncol; 2015 Mar; 33(8):836-45. PubMed ID: 25667292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma.
    Chera BS; Amdur RJ; Green R; Shen C; Gupta G; Tan X; Knowles M; Fried D; Hayes N; Weiss J; Grilley-Olson J; Patel S; Zanation A; Hackman T; Zevallos J; Blumberg J; Patel S; Kasibhatla M; Sheets N; Weissler M; Yarbrough W; Mendenhall W
    J Clin Oncol; 2019 Oct; 37(29):2661-2669. PubMed ID: 31411949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of Human Papilloma Virus status on the prediction of head and neck cancer chemoradiotherapy outcomes using the pre-treatment apparent diffusion coefficient.
    Connor S; Anjari M; Burd C; Guha A; Lei M; Guerrero-Urbano T; Pai I; Bassett P; Goh V
    Br J Radiol; 2022 Feb; 95(1130):20210333. PubMed ID: 34111977
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
    de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
    Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.
    O'Sullivan B; Huang SH; Siu LL; Waldron J; Zhao H; Perez-Ordonez B; Weinreb I; Kim J; Ringash J; Bayley A; Dawson LA; Hope A; Cho J; Irish J; Gilbert R; Gullane P; Hui A; Liu FF; Chen E; Xu W
    J Clin Oncol; 2013 Feb; 31(5):543-50. PubMed ID: 23295795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma.
    Chera BS; Amdur RJ; Tepper JE; Tan X; Weiss J; Grilley-Olson JE; Hayes DN; Zanation A; Hackman TG; Patel S; Sheets N; Weissler MC; Mendenhall WM
    Cancer; 2018 Jun; 124(11):2347-2354. PubMed ID: 29579339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploring the Impact of Human Papillomavirus Status, Comorbidity, Polypharmacy, and Treatment Intensity on Outcome of Elderly Oropharyngeal Cancer Patients Treated With Radiation Therapy With or Without Chemotherapy.
    Caparrotti F; O'Sullivan B; Bratman SV; Ringash J; Lu L; Bayley A; Cho J; Giuliani M; Hope A; Kim J; Waldron J; Hansen A; Goldstein D; Perez-Ordonez B; Weinreb I; Tong L; Song Y; Xu W; Huang SH
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):858-867. PubMed ID: 28258893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomes.
    Lin TA; Garden AS; Elhalawani H; Elgohari B; Jethanandani A; Ng SP; Mohamed AS; Frank SJ; Glisson BS; Debnam JM; Sturgis EM; Phan J; Reddy JP; Fuller CD; Morrison WH; Skinner HD; Rosenthal DI; Gunn GB
    Cancer; 2019 May; 125(9):1536-1546. PubMed ID: 30620385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T-category remains an important prognostic factor for oropharyngeal carcinoma in the era of human papillomavirus.
    Mackenzie P; Pryor D; Burmeister E; Foote M; Panizza B; Burmeister B; Porceddu S
    Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):643-7. PubMed ID: 25001635
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rethinking the 10-pack-year rule for favorable human papillomavirus-associated oropharynx carcinoma: A multi-institution analysis.
    Broughman JR; Xiong DD; Moeller BJ; Contrera KJ; Prendes BL; Lamarre ED; Ku JA; Burkey BB; Woody NM; Joshi NP; Adelstein DJ; Geiger JL; Frenkel CH; Milas ZL; Brickman DS; Sumrall AL; Carrizosa DR; Greskovich JF; Koyfman SA; Ward MC
    Cancer; 2020 Jun; 126(12):2784-2790. PubMed ID: 32167593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcomes and prognostic factors in cisplatin versus cetuximab chemoradiation for locally advanced p16 positive oropharyngeal carcinoma.
    Barney CL; Walston S; Zamora P; Healy EH; Nolan N; Diavolitsis VM; Neki A; Rupert R; Savvides P; Agrawal A; Old M; Ozer E; Carrau R; Kang S; Rocco J; Teknos T; Grecula JC; Wobb J; Mitchell D; Blakaj D; Bhatt AD
    Oral Oncol; 2018 Apr; 79():9-14. PubMed ID: 29598954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment outcomes in oropharynx cancer patients who did not complete planned curative radiotherapy.
    Alfaraj F; Craig T; Huang SH; O'Sullivan B; Su J; Bayley A; Bratman S; Cho J; Giuliani M; Kim J; Ringash J; Waldron J; Hansen A; de Almeida J; Perez-Ordonez B; Weinreb I; Tong L; Xu W; Hope A
    Oral Oncol; 2019 Oct; 97():124-130. PubMed ID: 31521053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus-Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy.
    Tsai CJ; McBride SM; Riaz N; Kang JJ; Spielsinger DJ; Waldenberg T; Gelblum D; Yu Y; Chen LC; Zakeri K; Wong RJ; Dunn L; Pfister DG; Sherman EJ; Lee NY
    JAMA Oncol; 2022 Mar; 8(3):364-372. PubMed ID: 35050342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer.
    Lassen P; Primdahl H; Johansen J; Kristensen CA; Andersen E; Andersen LJ; Evensen JF; Eriksen JG; Overgaard J;
    Radiother Oncol; 2014 Dec; 113(3):310-6. PubMed ID: 25544647
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.